Systemic therapy of atopic dermatitis with Janus kinase inhibitors

Q3 Medicine

Allergo Journal International Pub Date : 2025-08-19 DOI:10.1007/s40629-025-00345-9

Thomas Bieber MDRA

{"title":"Systemic therapy of atopic dermatitis with Janus kinase inhibitors","authors":"Thomas Bieber MDRA","doi":"10.1007/s40629-025-00345-9","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Over the last 8 years, the treatment of atopic dermatitis (AD) has been revolutionized by the development and approval of novel systemic therapies. In addition to the biologics dupilumab, tralokinumab, lebrikizumab, and nemolizumab, the three Janus kinase inhibitors (JAKi) baricitinib, abrocitinib, and upadacitinib are now also available.</p><h3>Methods and results</h3><p>A selection of the most important publications on the approved JAKi for the systemic treatment of AD and their statements were used as the basis for this review.</p><h3>Conclusion</h3><p>Systemic JAKi have become established as a promising therapeutic option in the guidelines for the treatment of AD. They specifically block the JAK signaling pathways involved in the inflammatory response and provide rapid and effective relief of the inflammatory reaction as well as the symptoms such as itching and pain. Compared to the class of biologics, they have a broader effect on various cytokines. Despite very good efficacy, there are some safety concerns, which is why a careful risk–benefit assessment is required in accordance with European Medicines Agency recommendations.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 6","pages":"167 - 172"},"PeriodicalIF":0.0000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergo Journal International","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1007/s40629-025-00345-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Over the last 8 years, the treatment of atopic dermatitis (AD) has been revolutionized by the development and approval of novel systemic therapies. In addition to the biologics dupilumab, tralokinumab, lebrikizumab, and nemolizumab, the three Janus kinase inhibitors (JAKi) baricitinib, abrocitinib, and upadacitinib are now also available.

Methods and results

A selection of the most important publications on the approved JAKi for the systemic treatment of AD and their statements were used as the basis for this review.

Conclusion

Systemic JAKi have become established as a promising therapeutic option in the guidelines for the treatment of AD. They specifically block the JAK signaling pathways involved in the inflammatory response and provide rapid and effective relief of the inflammatory reaction as well as the symptoms such as itching and pain. Compared to the class of biologics, they have a broader effect on various cytokines. Despite very good efficacy, there are some safety concerns, which is why a careful risk–benefit assessment is required in accordance with European Medicines Agency recommendations.

查看原文本刊更多论文

Janus激酶抑制剂对特应性皮炎的全身治疗

在过去的8年里，随着新型全身疗法的开发和批准，特应性皮炎（AD）的治疗发生了革命性的变化。除了生物制剂dupilumab， tralokinumab， lebrikizumab和nemolizumab，三种Janus激酶抑制剂（JAKi） baricitinib， abrocitinib和upadacitinib现在也可用。方法与结果选择已批准的用于系统治疗AD的JAKi的最重要的出版物及其声明作为本综述的基础。结论在AD的治疗指南中，全身性JAKi已成为一种有前景的治疗选择。它们特异性阻断参与炎症反应的JAK信号通路，快速有效地缓解炎症反应以及瘙痒、疼痛等症状。与一类生物制剂相比，它们对各种细胞因子具有更广泛的作用。尽管疗效非常好，但存在一些安全问题，这就是为什么需要根据欧洲药品管理局的建议进行仔细的风险-收益评估。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Allergo Journal International Medicine-Immunology and Allergy

CiteScore

4.60

自引率

0.00%

发文量

期刊介绍： Allergo Journal International is the official Journal of the German Society for Applied Allergology (AeDA) and the Austrian Society for Allergology and Immunology (ÖGAI). The journal is a forum for the communication and exchange of ideas concerning the various aspects of allergy (including related fields such as clinical immunology and environmental medicine) and promotes German allergy research in an international context. The aim of Allergo Journal International is to provide state of the art information for all medical and scientific disciplines that deal with allergic, immunological and environmental diseases. Allergo Journal International publishes original articles, reviews, short communications, case reports, and letters to the editor. The articles cover topics such as allergic, immunological and environmental diseases, the latest developments in diagnosis and therapy as well as current research work concerning antigens and allergens and aspects related to occupational and environmental medicine. In addition, it publishes clinical guidelines and position papers approved by expert panels of the German, Austrian and Swiss Allergy Societies. All submissions are reviewed in single-blind fashion by at least two reviewers. Originally, the journal started as a German journal called Allergo Journal back in 1992. Throughout the years, English articles amounted to a considerable portion in Allergo Journal. This was one of the reasons to extract the scientific content and publish it in a separate journal. Hence, Allergo Journal International was born and now is the international continuation of the original German journal. Nowadays, all original content is published in Allergo Journal International first. Later, selected manuscripts will be translated and published in German and included in Allergo Journal.